Betaxolol HCl Ophthalmic Solution Rx
Generic Name and Formulations:
Betaxolol HCl 0.5%; oph soln; contains benzalkonium chloride.
Indications for Betaxolol HCl Ophthalmic Solution:
Open-angle glaucoma. Ocular hypertension.
1–2 drops in affected eye(s) twice daily. Concomitant therapy with pilocarpine and other miotics, and/or epinephrine and/or carbonic anhydrase inhibitors can be instituted if needed.
Sinus bradycardia. Greater than 1st-degree AV block. Cardiogenic shock. Overt cardiac failure.
History of cardiac failure or heart block. Discontinue at 1st sign of cardiac failure. Asthma. Pulmonary impairment. Diabetes (esp. labile). May mask hypoglycemia and hyperthyroidism. May potentiate muscle weakness. Discontinue before general anesthesia. Avoid abrupt cessation. Pregnancy (Cat.C). Nursing mothers.
May potentiate or be potentiated by systemic β-blockers. May potentiate reserpine, hypoglycemics. May antagonize adrenergic psychotropics.
Transient discomfort, tearing. Rarely: decreased corneal sensitivity, erythema, itch, corneal punctate staining, keratitis, anisocoria, photophobia, depression, headache, bradycardia, dyspnea, hives.
Formerly known under the brand name Betoptic.
Soln—5mL, 10mL, 15mL
Endocrinology Advisor Articles
- Cushing Syndrome Results in Poor Quality of Life Even After Remission
- DPP-4 Inhibitors and Incidence of Rheumatoid Arthritis in Type 2 Diabetes
- Cost-Benefit Analysis of Insulin Analogs in Type 2 Diabetes
- Nonfunctioning Adrenal Incidentaloma Associated With Metabolic Syndrome
- Low Predictive Power of Biomarkers for Estimated Glomerular Filtration Rate Decline
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Link Between Gestational Diabetes and Risk for CVD and Diabetes in Hispanic/Latina Population
- Clinical Characteristics Altering Risks and Benefits of Sulfonylureas and Thiazolidinedione Therapy in T2D
- 6 Factors Related to Inclusion in Health Care Workplace Identified
- Weight Gain After Quitting Smoking May Increase Risk for T2D